POMC and epilepsy syndrome: Eight compounds that were approved in the US for treatment of rare seizure conditions and epilepsy syndromes were not submitted for orphan drug designation in the EU, i.e. clobazam, diazepam viscous solution for rectal administration, felbamate, fosphenytoin, lamotrigine, repository corticotropin or adrenocorticotropic hormone, topiramate, and vigabatrin.